Genomic Health Oncotype DX AR-V7 Nucleus Detect
Genomic Health has launched the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy assay intended to predict treatment response in men with advanced prostate cancer. Developed and performed by circulating tumor cell firm Epic Sciences, the new assay is the first of its kind to be commercially marketed. The test detects the presence of a splice variant of the androgen receptor protein in the nucleus of CTCs using Epic's detection and analysis platform.
The presence of AR-V7 has been shown in research studies to be predictive of whether men will respond to androgen receptor-signaling inhibitors like enzalutamide and abiraterone, or might be better served by chemotherapy.